Floatz logo

IBUPROFEN

Pain, Acute

Washington University School of MedicineSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Pain, Acute cohort.

Asset / SponsorPhaseRating
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
King Saud University
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Brian Anderson, MD
Phase 4BB
CISATRACURIUM ION
Medical University of Lublin
Phase 4BB
RAMIFENTANYL
Evangelismos Hospital
Phase 4BB
PROPOFOL
Evangelismos Hospital
Phase 4BB

View all 27 →

Same molecule, other indications

IBUPROFEN is also rated in:

chronic pain syndromeDormant
BBB
Indicative ·
72 / 100
View asset →
migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →